<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615250</url>
  </required_header>
  <id_info>
    <org_study_id>ISCIC-2012</org_study_id>
    <nct_id>NCT01615250</nct_id>
  </id_info>
  <brief_title>Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy</brief_title>
  <acronym>ISCIC</acronym>
  <official_title>Phase I Study to Evaluate the Efficacy and Safety of Intramyocardial Implantation of Peripheral Mononuclear Cells With CD34+ Stem Cells in Patient With Ischemic Cardiomyopathy After Preparatory Course of Shock - Wave Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odessa National Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odessa National Medical University</source>
  <brief_summary>
    <textblock>
      This is a randomized study of efficiency and safety of intramyocardial implantation of
      peripheral mononuclear cells with high concentration of CD34+ stem cells in patients with
      myocardial ischemia after preparatory course of shock - wave therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global left ventricular ejection fraction and regional wall motion score index</measure>
    <time_frame>6 and12 months</time_frame>
    <description>Change in global left ventricular ejection fraction and regional wall motion score index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of the major adverse cardiac events</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Incidence of the major adverse cardiac events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment with standard therapy. Cardiospec shock-wave therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramyocardial implantation of stem cells</intervention_name>
    <description>Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Ð¡ell concentration is 200 million cells in 1 ml.</description>
    <arm_group_label>Stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ischemic cardiomyopaty and HF II-IV NYHA class

          -  MI more than 6 months before the study

          -  LVEF less than 35%

          -  Absence effect of coronary revascularization during 6 months

          -  Optimal pharmacological therapy no less than 8 weeks

          -  Heart transplantation is contraindicated

          -  Patients with implantable cardioverter-defibrillator (ICD) or cardiac
             resynchronization therapy defibrillator (CRT-D)

          -  Patients giving informed consent

        Exclusion Criteria:

          -  Acute coronary syndrome

          -  Coronary revascularization less than 6 months

          -  Patients requiring surgical correction of post-MI aneurism

          -  LV wall thickness less than 5 mm in site of possible injection

          -  Patients with CRT implanted within 3 month before cells injection

          -  Clinically significant associated diseases

          -  Active oncology desiase

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iurii I Karpenko, Dr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odessa National Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iurii I Karpenko, Dr, PhD</last_name>
    <phone>+38048750113</phone>
    <phone_ext>+38048750113</phone_ext>
    <email>arcard2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odessa Regional Clinical Hospital</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iurii I Karpenko, Dr, PhD</last_name>
      <phone>+380487500115</phone>
      <phone_ext>+380487500115</phone_ext>
      <email>arcard2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odessa National Medical University</investigator_affiliation>
    <investigator_full_name>Iurii Kozlov</investigator_full_name>
    <investigator_title>Dr., PhD Iurii I Karpenko</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

